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The study was naturalistic and thus the aim was to investigate
the impact of remission in clinical practice, without any pre-
speciﬁed protocol for the GPs to follow. Cox regression analysis
was employed to analyse what factors inﬂuence the time to
achieve remission. RESULTS: Fifty-two percent of the patients
achieved remission during the study period. During a period of
six months, remitting patients have on average three outpatient
care visits less than non-remitting patients (p = 0.0001), and 
substantially less sick-leave days: 22 days per year (p = 0.0106).
Remitting patients have a signiﬁcantly lower total cost ($3,400
during 6 months) compared with non-remitting patients (p =
0.0001). Moreover, the average EQ-5D index score was 0.24
higher in remitting patients (p = 0.0001). Severely depressed
patients have 60% lower chance of achieving remission quickly
than milder cases of depression (p = 0.002). CONCLUSIONS:
Remission has a substantial health economic impact and we have
shown both statistically signiﬁcant reductions in cost as well as
improved quality-of-life. Our results argue for the importance of
aiming for full remission in the antidepressive treatment of
depression, and hence indicating that antidepressants that
rapidly lead to full remission may be cost-effective.
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OBJECTIVE: To identify utility weights for use in cost-utility
analyses of antidepressants. METHODS: Systematic search of
MEDLINE using search terms for depression and utility/prefer-
ence weights. Utility weights by depression severity and changes
in utility by response to treatment were abstracted. Methods
used to derive utilities were cross-tabulated with the values
obtained. RESULTS: Six published studies were reviewed. Three
studies obtained utility weights using the standard gamble (SG)
method, one study used the SG and time trade-off (TTO)
methods, one study used the EQ5D TTO weights, and one study
used the quality of well being (QWB) scale weights. One of the
SG studies compared utility for those with and without depres-
sion over a 10-year time horizon (0.942 (standard deviation (SD)
0.159) versus 0.963 (SD 0.144)). The other three SG studies
compared utility for different depression severity and, depend-
ing on the whether the SG lottery was presented for temporary
or lifetime health states, estimated utilities for severe depression
were between 0.09 (SD 0.02) and 0.813 (SD 0.209) and for mild
depression were between 0.59 (SD 0.02) and 0.871 (SD 0.184).
Three of the six reviewed studies compared the gain in utility for
those who responded to treatment to those who did not. The
gain in utility for responders compared to non-responders in
these studies was: 0.053 at 1 year using the SG lifetime method;
0.180 at 4 months using the QWB weights; and 0.220 at 2
months using the EQ5D TTO weights. CONCLUSIONS: Pub-
lished estimates of utility weights for people with depression and
of the gains in utility in people recovering from depression vary
considerably depending on the method of assessment. We rec-
ommend that utility gains for antidepressant treatments be esti-
mated using SG for temporary health states along with sensitivity
analyses using alternative methods of utility assessment.
NEUROLOGICAL DISORDERS—Clinical Outcomes
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OBJECTIVES: Estimate clinical effectiveness and health out-
comes of short-term DMT that delays disability progression in
relapsing/remitting-onset deﬁnite MS (RR-onset MS). Nova
Scotia (NS) natural history data (1979–March 2004) and MS
Special Therapies Program (STP) data (July 1998–March 2004)
are analyzed. The STP provides universal full-cost coverage of
Avonex®, Betaseron®, Copaxone®, Rebif6® and Rebif12® for
RR-onset MS, as insurer of last-resort. METHODS: Extended
Disability Status Scale (EDSS) natural history (NH) increase per
year, increase avoided per DMT-year, and DMT effect size rela-
tive to NH are estimated using well-validated data (9,238 clinic
visits by 1435 persons with RR-onset MS) from the Dalhousie
MS Research Unit (DMSRU) clinic. Models estimate EDSS paths
from years-since-onset (yso) given “conventional care” or DMT.
NH data is from never-DMT-plus-ever-DMT persons or 
ever-DMT persons. Analysis is stratiﬁed by “ﬁnal” class [relaps-
ing/remitting (RRMS) or secondary progressive (SPMS)] and six
severity-yso data-cells (EDSS <= 0.5, 4 <= DSS <= 0.5; yso <= 0,
yso <= 0, yso <= 0. Health outcomes (HO), measured as EDSS-
Disability-Adjusted-Life-Years (DALYs) avoided or Health
Utility Index Mark III (HUI3)-Quality-Adjusted-Life-Years
(QALYs) gained, are estimated for DMT-treatment and post-
treatment periods. RESULTS: Estimates of annual EDSS NH
increase are much smaller for RRMS than SPMS subgroups,
larger for “ever-treated” than “never-treated” subgroups, and
increase with years-since-onset. Estimates of EDSS increase
avoided per DMT-year vary by “ﬁnal” class, NH controls, 
severity-yso data-cells and DMT-duration. Effect size relative to
NH is larger in earlier years-since-onset when disability is
“mild”, than in later years when disability is “moderate” and
more patients are SPMS. Health outcomes in DMT-periods and
post-DMT-periods increase rapidly with DMT-duration. QALY
estimates > DALY estimates. CONCLUSIONS: Short-term DMT
delays disability progression in RR-onset MS. “Real world”
DMT effectiveness estimates complement clinical trial efﬁcacy
estimates. Both contribute to models of long-term DMT effec-
tiveness, health outcomes, costs and cost-effectiveness, which
inform debates on DMT practice guidelines, treatment eligibil-
ity criteria and funding.
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OBJECTIVES: Treatment may help decrease the symptoms of
restless legs syndrome (RLS), but it is unclear how many people
with RLS receive medical care. This study sought to determine
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the proportion of patients treated for RLS in a large claims data-
base. METHODS: We identiﬁed patients with at least one RLS
diagnosis (ICD-9 333.99) between 1999 and 2003 in Medstat’s
MarketScan Commercial Claims and Encounters database of de-
identiﬁed insurance claims from employees and dependents. We
estimated treated RLS by calculating the proportion of patients
in the database with a ﬁrst-time RLS diagnosis (incidence) and
with an RLS diagnosis anytime (prevalence). RESULTS: Inci-
dence of RLS treatment increased slightly each year, from 0.3402
per 1,000 persons in 1999 to 0.4494 per 1,000 in 2003. Preva-
lence also rose, reaching 0.5414 per 1,000 in 2003. Prevalence
rates per 1,000 in 2003 by age group were: ages 1–17, 0.0330;
ages 18–34, 0.1845; ages 35–44, 0.5848; ages 45–54, 1.0049;
and ages 55–64, 1.3069. Prevalence for women per 1,000 was
0.6576 compared to 0.4126 for men. US geographic regions with
the highest rates were North Central (0.6842) and South
(0.5686), with lower rates seen in Northeast (0.4074) and West
(0.4172). Higher rates of RLS (1.8621 vs. 0.3259 per 1000) were
found among patients who had any characteristic that put them
at “high risk” for RLS (anemia, end-stage renal disease, diabetes,
rheumatoid arthritis, pregnancy or SSRI use). CONCLUSIONS:
Rates of treated RLS were higher among older patients, women,
and those with “high risk” factors, consistent with previous
research. Compared to RLS prevalence estimates from popula-
tion-based studies, rates were low in our sample. Additional
research may help to understand the large differences in these
prevalence estimates.
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OBJECTIVES: Comparing length of stay by anticonvulsant
therapy may be the ﬁrst step to identifying adverse events asso-
ciated with treatment as well as treatment effectiveness. This
study attempts to determine the association between the hospi-
tal length of stay and the use of anticonvulsants by inpatients
with seizure disorders. METHODS: A cohort of 126,362
patients admitted to U.S. hospitals from July 1, 2004 to June 30,
2005 with a diagnosis of seizure or epilepsy was constructed
using data from Premier’s Perspective Comparative Database.
Anticonvulsant use was tracked throughout each patient’s 
hospital stay and patients were categorized by drug into carba-
mazepine, clonazepam, divaloprex, fosphenytoin, gabapentin,
lamotrigine, magnesium, oxcarbazepine, phenytoin, topiramate,
valproic acid, levetiracetam, and other anticonvulsants groups.
Descriptive statistics including demographic characteristics and
drug utilization were reported for the sample. Mixed regression
models were used to control for selection bias due to patient clus-
tering within hospitals. The model observed the impact of anti-
convulsant monotherapy by drug on length of stay. RESULTS:
Mean length of stay for non-users were 5.63 (SD = 9.02) and
drug users ranged between topiramate users with 5.42 (SD =
6.20) and magnesium users with 12.99 (SD = 18.27). Clon-
azepam (t = 5.41, p < 0.0001), divaloprex (t = 5.09, p < 0.0001),
gabapentin (t = 7.25, p < 0.0001), magnesium (t = 40.76, p <
0.0001) and phenytoin (t = 7.58, p < 0.0001) were signiﬁcantly
associated with length of stay while controlling for race, gender,
age, severity of illness and admission status. CONCLUSIONS:
Further analysis should investigate patterns of events associated
with increased length of stay in patients taking clonazepam,
divaloprex, gabapentin, magnesium, and phenytoin for identiﬁ-
cation of potential adverse events.
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OBJECTIVES: The oral prophylactic medications currently uti-
lized in the management of migraine headache have been shown
to exhibit varying responsiveness in terms of reduction of
headache burden. It is the objective of this model to be used as
tool to compare the relative cost-effectiveness (CE) of these
agents vs. botulinum toxin type A (BOTOX®/BTX-A) from a
payer perspective. METHODS: An interactive Excel-based
model was developed to compare the relative CE of the avail-
able oral prophylactic medications vs. BTX-A in the treatment
of migraine headache. Drug effectiveness with respect to reduc-
tion in headache burden and utilization of acute medications was
based on the published literature. Drug costs were based on
average wholesale price with consideration of contractual dis-
counts and patient co-payment. The primary economic end-
points were the drug cost per headache (HA) and headache day
(HAD) for episodic migraine and chronic migraine respectively.
Multi-factor sensitivity analyses were conducted. RESULTS: In
the management of episodic migraine, the oral prophylactic 
medications offered a cost per HA avoided varying from US$48
(divalproex sodium/Depakote®) to US$138 (gabapentin/
Neurontin®). In the management of chronic migraine, BTX-A
offered a cost per HAD avoided of US$17. Total migraine related
drug costs (inclusive of both acute and prophylactic medications)
were found to be unchanged with the utilization of BTX-A due
to the offsetting reduction in acute medication use associated
with BTX-A therapy. CONCLUSION: Modeling CE in terms of
reduction in headache burden provides a methodology for com-
paring clinical trials and demonstrates that the relative difference
in CE between the oral prophylactic medications and BTX-A in
the management of migraine headache is signiﬁcant.
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OBJECTIVES: Clinical trials establishing the efﬁcacy of disease
modifying drugs (DMDs) utilized in treating relapsing forms of
Multiple Sclerosis (MS) have been based on populations of
varying baseline relapse rates and disability burden. It is the
objective of this model to be used as a tool to compare the 
relative cost-effectiveness (CE) of these drugs from a payer 
perspective. METHODS: An interactive Excel-based model was
developed to compare the relative cost components of relapses,
disability progression, and DMDs in the treatment of MS. Drug
effectiveness with respect to reduction in relapses and the
slowing of disability progression was derived from the published
Level I clinical trial data and was based on absolute risk reduc-
tion (ARR) in clinical events to account for differences between
study populations. Cost data was based on work by O’Brien and
colleagues, and disability progression data was based on research
by Weinshenker and colleagues. Drug costs were based on
